tbuckley/cabot-search huggingface dataset:
Prognosis, diagnostic delay, and patient characteristics associated with diagnostic delay among Kaposi sarcoma (KS) patients in Uganda.
Authors: Christopher De Boer, Nixon Niyonzima, Jackson Orem, John Bartlett, Yousuf Zafar
Journal: Journal of Clinical Oncology (2013)

6578 Background: The incidence and mortality of KS remain high in sub-Saharan Africa. Delaying treatment might explain poor outcomes, but no study has measured the association between delay, characteristics associated with delay, and prognosis for KS patients in low- and middle-income countries. Methods: This is a prospective, cross-sectional study conducted from June-October 2012 at the Uganda Cancer Institute (UCI) in Kampala, Uganda among HIV-infected adults with histologically confirmed KS. The aim was to measure the association between delay and overall KS stage risk at diagnosis. Standardized interviews were conducted in English or Luganda to measure delay, and medical records were abstracted to obtain KS stage at admission to UCI. Multivariable logistic regression was used to assess the relationship between diagnostic delay and poor-risk stage at diagnosis. Results: 161 patients were enrolled; 68.9% were men, mean age was 34.0 years (SD 7.7), 58.1% had income &lt; $2 per day, and 49.4% had ≥primary education. 25.8% had been seen in an HIV clinic within 3 months, 71.6% were on antiretroviral therapy (ART), and 25.5% had visited a traditional healer prior to being seen at UCI. 45.3% delayed seeking care at UCI for ≥3 months from onset of symptoms. Among those who delayed, 35.6% waited 6 months, and 24.7% waited 12 months. The most common reasons for delay were lack of pain (47.9%), no money (31.5%), and distance to UCI (8.2%). In adjusted analysis patients who experienced diagnostic delay were more likely to have poor-risk stage compared to those who did not delay (OR 3.41, p=0.002, 95%CI: 1.46-7.45). After adjusting for patient characteristics, HIV clinic attendance, and ability to pay out-of-pocket costs, visiting a traditional healer was the only characteristic associated with greater likelihood of delay (OR 2.69, p=0.020, 95%CI: 1.17-6.17). Conclusions: Diagnostic delay was independently associated with poor-risk stage at diagnosis, and visiting a traditional healer was the only patient characteristic independently associated with delay. The relationship between traditional and Western medicine presents a critical point of intervention to improve KS outcomes in Uganda.
Long Term Follow-up of the Prospective Multicenter Study of reduced-Intensity Allogeneic Stem Cell Transplantation for Primary or Post ET/PV Myelofibrosis
Authors: Haefaa Alchalby, Tatjana Zabelina, Daniel Wolff, Guido Kobbe, Martin Bornhäuser, Herrad Baurmann, Arnon Nagler, Wolfgang A. Bethge, Matthias Stelljes, Lutz Uharek, Kerstin Schaefer-Eckert, Andreas Burchert, Paolo Corradini, Joerg E. A. Schubert, Martin Kaufmann, Peter Dreger, Gerald Wulf, Gernot Stuhler, Hans-Michael Kvasnicka, Axel R. Zander, Dietger Niederwieser, Ronald Brand, Theo M. de Witte, Nicolaus Kröger
Journal: Blood (2011)
An oxidative stress-based mechanism of doxorubicin cytotoxicity suggests new therapeutic strategies in ABC-DLBCL
Authors: Yun Mai, J. Jessica Yu, Boris Bartholdy, Zijun Y. Xu-Monette, Esther E. Knapp, Fei Yuan, Hongshan Chen, B. Belinda Ding, Zhihua Yao, Bhaskar Das, Yiyu Zou, Ken He Young, Samir Parekh, B. Hilda Ye
Journal: Blood (2016)
P556 INTER-ALPHA TRYPSIN INHIBITOR HEAVY CHAIN H4 AS DIAGNOSTIC AND PROGNOSTIC INDICATOR IN PATIENTS WITH HEPATITIS B VIRUS ASSOCIATED HEPATOCELLULAR CARCINOMA
Authors: S.S. Kim, C.K. Noh, H.J. Cho, S.J. Ahn, S.W. Cho, J.Y. Cheong
Journal: Journal of Hepatology (2014)
Phase I expansion trial of an oral TORC1/TORC2 inhibitor (CC-223) in diffuse large B-cell lymphoma (DLBCL) and multiple myeloma (MM).
Authors: Andre Goy, Vincent Ribrag, Andrea Varga, Thomas E. Witzig, Enrique M. Ocio, Luis G. Paz-Ares, Monica M. Mita, Tim Meyer, Pamela N. Munster, Amit Mahipal, Jean-Pierre Delord, Hendrik-Tobias Arkenau, Martin Gutierrez, Angela James, Lilly Wong, Shuichan Xu, Xiaoling Wu, James Carmichael, Rajesh Chopra, Kristen Hege
Journal: Journal of Clinical Oncology (2013)

8522 Background: CC-223 is an ATP-competitive inhibitor of the mTOR kinase, including both TORC1 and TORC2 complexes. CC-223 was selected to address resistance of rapamycin analogues mediated by TORC2 activation. Methods: Following establishment of the MTD (reported at ASCO 2012), subjects with advanced DLBCL, MM and select solid tumors were enrolled in parallel expansion cohorts of up to 20 evaluable subjects. CC-223 was dosed at 45 mg once daily in 28 day cycles until disease progression. Results: As of 09 January, 2013, 35 subjects were enrolled including DLBCL (21) and MM (14). Results in solid tumor cohorts are reported separately. The most common (&gt; 20%) related adverse events (all grades) were fatigue, hyperglycemia, rash, anorexia, nausea, vomiting and diarrhea. In addition, related serious adverse events included infection (2), pneumonitis (1), renal insufficiency (2), pancreatitis (1) and thrombocytopenia (1). CC-223 dose reduction was required in 9 subjects (27%), usually during cycle 1 or 2, and 4 additional subjects with DLBCL dropped out during cycle 1 due to toxicity. Systemic exposure was similar between the two tumor cohorts and was associated with inhibition of TORC1 (p4EBP1) and TORC2 (pAKT) biomarkers in blood cells. Reduction in glucose uptake (32 – 98% decrease) on PET imaging at day 15 was observed in 7/7 DLBCL subjects with results currently available. Three of 17 evaluable subjects with DLBCL had partial responses (PR) after 2 cycles; two with rapid and near complete regression (&gt; 90%) of target lesions by CT and PET with PR confirmed and treatment ongoing at 6 and 8 cycles. Both had failed multiple prior treatment regimens (5 and 3, respectively), including autologous stem cell transplant (ASCT). No responses were observed in 10/14 evaluable subjects with MM although 2 subjects have prolonged stable disease (SD) with treatment ongoing at 12 and 14 cycles. Conclusions: Encouraging signals of biomarker and clinical activity were observed in DLBCL, including two near complete responses, which are ongoing. Due to dose reductions and interruptions, a starting dose of 30 mg QD is recommended for future studies. Clinical trial information: NCT01177397.
Genome-wide association studies of autoimmune vitiligo identify 23 new risk loci and highlight key pathways and regulatory variants
Authors: Ying Jin, Genevieve Andersen, Daniel Yorgov, Tracey M Ferrara, Songtao Ben, Kelly M Brownson, Paulene J Holland, Stanca A Birlea, Janet Siebert, Anke Hartmann, Anne Lienert, Nanja van Geel, Jo Lambert, Rosalie M Luiten, Albert Wolkerstorfer, J P Wietze van der Veen, Dorothy C Bennett, Alain Taïeb, Khaled Ezzedine, E Helen Kemp, David J Gawkrodger, Anthony P Weetman, Sulev Kõks, Ele Prans, Külli Kingo, Maire Karelson, Margaret R Wallace, Wayne T McCormack, Andreas Overbeck, Silvia Moretti, Roberta Colucci, Mauro Picardo, Nanette B Silverberg, Mats Olsson, Yan Valle, Igor Korobko, Markus Böhm, Henry W Lim, Iltefat Hamzavi, Li Zhou, Qing-Sheng Mi, Pamela R Fain, Stephanie A Santorico, Richard A Spritz
Journal: Nature Genetics (2016)
TCT-315 Variation in Collagen in the Caps of Human Coronary Lipid-core Plaque Autopsy Specimens: A Possible Measure of Cap Weakness
Authors: Jimmy Su, Stephanie J. Grainger, Cherry Greiner, Matthew D. Saybolt, Robert Wilensky, Joel Raichlen, Sean Madden, James E. Muller
Journal: Journal of the American College of Cardiology (2015)
TCT-562 Comparison of Neointimal Growth Pattern after Thin- or Thick- Strut Drug Eluting Stents Implanted in Coronary Bifurcation Lesions: an Optical Coherence Tomography Study
Authors: Makoto Watanabe, Hiroyuki Okura, Yoko Dote, Yu Sugawara, Tomoya Ueda, Tsunenari Soeda, Satoshi Okayama, Yoshihiko Saito
Journal: Journal of the American College of Cardiology (2015)
Treatment patterns by oncologists and urologists for castration-resistant prostate cancer (CRPC).
Authors: B. Alemayehu, N. M. Engel-Nitz, F. E. Nathan
Journal: Journal of Clinical Oncology (2010)

6083 Background: The literature reports little on the frequency of hormonal treatment in CRPC or on the variation by specialty of treating physician. This study compared patients treated by oncologists or urologists on use of hormones, other treatments and healthcare costs. Methods: A retrospective study design identified patients with CRPC using medical and pharmacy claims (2001-2007) from a large U.S. managed care health plan. Patients were stratified based upon the specialist providing treatment; oncologist (with/without urologist, ONC), or urologist without oncologist (URO). Index Date was defined as first indication of castration-resistance; 6-month baseline period assessed patient characteristics and initial clinical status and variable follow-up period (until disenrollment or 12/31/2008) assessed use of hormones, chemotherapy, radiation, and total and CPRC-related healthcare costs. Chi-square statistics compared proportions and t-tests compared means across cohorts. Results: 995 URO and 1590 ONC patients with CRPC were identified; average follow-up time was longer for the URO (568 days) than ONC cohort (550 days). Mean age was higher in URO patients than in ONC patients (75.52 vs. 71.05 years, p < 0.001). However, the URO cohort had a lower average Charlson comorbidity score (3.73 vs. 4.85, p < 0.001), fewer comorbid illnesses (10.09 vs. 11.14, p < 0.001), and were less likely to have other cancers (17.69% vs. 27.36%, p < 0.001) or to have used hormones, chemotherapy, radiation treatment during the baseline period. Over follow-up, 61.11% of URO patients used any hormones, compared with 75.41% of ONC patients (p < 0.001). Fewer patients in the URO group used chemotherapy over follow-up (10.15%), compared with ONC (46.86%, p < 0.001). Mean total health care costs were $15,318 (URO) and $31,896 (ONC), p < 0.001; mean CPRC costs were $6,474 for URO and $21,517 for ONC (p < 0.001). Conclusions: Use of hormone treatments by CRPC patients was common regardless of physician specialty. Although CRPC patients treated by urologists were older than patients treated by oncologists, they appeared to have less severe clinical status, reflected in comorbidity assessments, treatment patterns and lower health care costs. Author Disclosure Employment or Leadership Position Consultant or Advisory Role Stock Ownership Honoraria Research Funding Expert Testimony Other Remuneration AstraZeneca AstraZeneca
A Sensitized Whole Genome ENU Mutagenesis Screen Identifies an Arp2 Missense Mutation As a Novel Suppressor of Lethal Thrombosis in the Factor V Leiden Mouse
Authors: Randal Joseph Westrick, Guojing Zhu, Kart Tomberg, David R. Siemieniak, Sara A. Haynes, Jishu Xu, Jun Z. Li, David Ginsburg
Journal: Blood (2012)
GW27-e0852 Effects of plasma IL-17 and IL-18 on the prothrombotic risk in patients with atrial fibrillation
Authors: Boshui Huang, Qing Huang, Ying Chen, Fasheng Liang, Huayuan Zeng, Jianlin Liang, Shaoxin Zheng, Shuxian Zhou
Journal: Journal of the American College of Cardiology (2016)
GW27-e1217 NEW Mechanism Explaining Fluid overload in patient with diastolic Heart Failure or Heart Failure patient with preserved ejection fraction : When the veins cause hypertension in the artery
Authors: Thach Nguyen, Advait Soni, Ryan Phan, Truong DX Tran, Tung Mai, Duane Pinto
Journal: Journal of the American College of Cardiology (2016)
TCT-102 SAPIEN 3 implantation in failed surgical aortic bioprostheses: Matched comparison and Insights from the Valve-in-Valve International Data (VIVID) Registry
Authors: Moritz Seiffert, Hendrik Treede, Dominique Himbert, Susheel Kodali, David Jochheim, Julinda Mehilli, Matheus Simonato dos Santos, Axel Linke, Felix Woitek, Giora Weisz, Vinayak Bapat, Zhan Yun Lim, Didier Tchetche, Sabine Bleiziffer, Thomas Walther, Marco Barbanti, Helene Eltchaninoff, Eric Durand, Semih Buz, Christian Frerker, Stephan Windecker, Mohamed Abdel-Wahab, Konstantinos Spargias, Arend de Weger, Gudrun Feuchtner, Webb John, Danny Dvir
Journal: Journal of the American College of Cardiology (2015)
Impact in cost of new cytotoxic and biological agents for colorectal and lung cancer: A European model
Authors: B. Massuti, A. Burgos, A. Yuste, E. Alonso, E. Adrover Cebrián, J. Marti, J. Ponce, M. Cia, J. Ordovas, R. Rosell
Journal: Journal of Clinical Oncology (2008)

17520 Background: Development of an economic evaluation model to be applied to the costs of the systemic treatment of Colorectal (CRC) and Non-small Cell Lung Cancer (NSCLC) in Spain. Assess the differential impact of the use of new cytotoxic and biological agents approved for first and second line setting Methods: Medical Oncology Units based in Public Hospitals in Spain. Overall monthly cost per patient in Euros (€) has been calculated for every schedule including:drug cost (per mg) (theoretical 1.7 BSA), pumps and infusional devices; blood tests; image techniques; costs of preparation of drugs; staff-costs: nurse-time preparing and delivering treatment, pharmacist-time for validation and doctor-time for visit (public medium salary working hour as reference). Costs not accounted in the model are: premedication drugs, treatment of secondary effects; refunds; travel expenditures. Indirect and intangible costs were not considered. The model has been applied to the results of pivotal registration clinical trials for new drugs in colorectal and lung cancer in 1st or 2nd line and differential cost for life year gained (LYG) has been calculated for the differents clinical settings compared to control arm. Clinical trials were: TAX 317; BR.21; BOND, ECOG 4599, Hurwitz´s trial. Results: Drugs cost range is 91.4–97.4% of total amount in different schedules. Monthly cost of treatment in 2nd line for NSCLC are: Docetaxel 969,83 € (LYG=4.849 €); Pemetrexed 2.201,78 €; Erlotinib 2.102,27 € (LYG 12.613 €). For pretreated CRC CPT-Cetuximab 4.233,4 € (LYG 29.845 €). In 1st line NSCLC the monthly cost of combination of Bevacizumab and Carboplatin-Paclitaxel accounts for 3.731,52 € (LYG 22.389 €). In 1st line CRC the addition of Bevacizumab to IFL achieves a monthly cost of 2.055,33 € (LYG 5.241 €). Conclusions: New cytotoxic and biologics drugs approved for the treatment of NSCLC and CRC cause a significant incremental cost for the treatment of these neoplasms. In 1st line setting the incremental cost is higher for NSCLC and in 2nd or 3rd line the cost of LYG is higher in CRC Author Disclosure Employment or Leadership Consultant or Advisory Role Stock Ownership Honoraria Research Expert Testimony Other Remuneration Eli Lilly, Roche
Are Stromal Cells of Adipose Tissue From Multiple Myeloma Patients Are Normal ? A Comparison of Adipose Derived Stromals Cells From Healthy Donors and Multiple Myeloma Patients
Authors: Benjamin Hebraud, Elodie Labat, Nicolas Espagnolle, Melanie Gadelorge, Louis Casteilla, Luc Sensebé, Murielle Roussel, Anne Huynh, marie-Veronique Joubert, Jill Corre, Herve avet-Loiseau, Michel Attal, Philippe Bourin
Journal: Blood (2012)
TCT-469 Differential effect of Side Branch Intervention on Long-term Clinical Outcomes According to Side Branch Stenosis after Main vessel Stenting: Results from the COBIS (Coronary Bifurcation Stenting) II Registry
Authors: Woo Jin Jang, Joo-Yong Hahn, Hyeon-Cheol Gwon, Ju Hyeon Oh
Journal: Journal of the American College of Cardiology (2015)
TCT-530 Biological Efficacy of a Novel Thin-Strut Sirolimus-Eluting Bioresorbable Scaffold in a Porcine Coronary Artery Model
Authors: Yanping Cheng, Lijie Wang, Edward A. Estrada, Jenn McGregor, Kamal Razipoor, Chang Lee, Pawel Gasior, Gaoke Feng, Gerard B. Conditt, Serge D. Rousselle, Greg L. Kaluza, Juan Granada
Journal: Journal of the American College of Cardiology (2015)
Assessing bronchodilator response in preschool children using spirometry
Authors: Luciano E Busi, Sebastián Restuccia, Ricardo Tourres, Peter D Sly
Journal: Thorax (2016)

Measuring lung function, including bronchodilator response (BDR), is an integral part of asthma management in older children. While spirometry is possible in preschool-aged children, the question remains whether measuring BDR aids in asthma diagnosis in this age group.431 healthy children and 289 children with asthma, aged 3-5 years, were recruited from kindergartens and the pulmonology clinic in Trelew, Argentina. Spirometry was performed at visit 1 and repeated after 15 min, with children randomised to placebo or salbutamol (400 µg). Spirometry was again performed within 8 weeks at visit 2. Within-session repeatability from visit 1 and between-session reproducibility were calculated using baseline spirometry. The within-session repeatability and receiver operating characteristic curve analyses were used to determine the optimal threshold values for BDR for spirometry outcome variables measured at the first visit, and sensitivity, specificity and diagnostic accuracy were determined.As a group, children with asthma had lower lung function (FVC 1.11±0.12 L vs 1.01±0.15 L; FEV0.75 1.01±0.10 L vs 0.91±0.15 L) and a greater BDR (FEV0.75 group difference 8.6 (95% CI -5.0 to 14.3)%) than healthy children. BDR was best defined by change in FEV0.75; an increase of 11% showed the best balance between sensitivity (51%), specificity (88%), positive predictive value (47%) and negative predictive value (89%) for discriminating healthy from preschool-aged children with asthma.A negative BDR in a child suspected of having asthma makes a diagnosis of asthma less likely.
Long-Term Follow-up of 94 Families with Myeloproliferative Neoplasms: Implications of the V617F JAK2 mutation, Life Expectancy and Complication Rates
Authors: Sandra Malak, Myriam Labopin, Isabelle Chaumarel, Cecile Saint-Martin, Christine Bellanne-Chantelot, Albert Najman
Journal: Blood (2010)
Cerebral Proliferative Angiopathy (CPA)
Authors: Egesta Lopci, Laura Olivari, Lorenzo Bello, Pierina Navarria, Arturo Chiti
Journal: Clinical Nuclear Medicine (2016)

We report the case of a 55-year-old woman with cerebral proliferative angiopathy (CPA). Her medical history included brain surgery for small vascular lesions and suspicion of cerebral malignancy. C methionine PET (C-METH PET) demonstrated a diffusely increased uptake on the right hemisphere. Contrast-enhanced MRI documented a massive lesion with a diffuse "nidus" appearance, involving the right cerebral hemisphere (sparing the inferior frontal gyrus and the anterior frontal lobe), the brainstem, and the middle cerebellar peduncle. Pathology confirmed the diagnosis of CPA and, after radiation treatment, the patient presented with clinical and radiological response.
TCT-812 Efficacy and Safety Evaluation of a Novel Endovascular Occlusion System in a Large Peripheral Preclinical Model
Authors: Armando Tellez, Leon Rudakov, Krista N. Dillon, Dane A. Brady, Philippe Gailloud, Serge D. Rousselle, Anthony C. Venbrux
Journal: Journal of the American College of Cardiology (2015)
Prognostic factors of overall survival for patients with stage II colon cancer treated at Sparrow Hospital from 1996–2006
Authors: G. Srkalovic, M. Maier, U. Chamarthy, L. DiCarlo, G. Pearce, J. Herman
Journal: Journal of Clinical Oncology (2008)

15089 Background: Although it is agreed that patients with stage III disease benefit from adjuvant treatment, whether all patients with stage II disease should receive such treatment remains debatable. In this study we analyzed factors influencing survival of patients with Stage II colon cancer seen and treated at Sparrow Hospital from February 1996 till January 2006. Methods: Included in the analysis were: age, gender, stage (IIA vs. IIB), surgery type, number of examined lymph nodes, pathological grade, tumor size and the use of chemotherapy. All survival analyses were performed using SAS system (V9.3, Cary NC). Results: Analysis was done on 187 patients with Stage II colon cancer age 71± 13 years (29 to 97). 108 patients were female (58 %) and 79 (42 %) males. Subtotal collectomy was performed on 134 (71 %), partial and total collectomy and partial resection on 37 (20%), 13 (7%) and 3 (2%) patients, respectively. Average number of removed lymph nodes was 18 ± 13 (1–103). Chemotherapy treatment ( 5-FU ± leucovorin) was given to 45 (24 %) patients, while the rest (142, 76 %) were followed expectantly. The mean length of follow up for all patients was 48 ± 33 months (0.1 - 133) and 56 ± 33 (0.2 - 133) for survivors. There were 85 deaths (45 %) recorded during the follow up. Overall survival for all patients was 90% at 12, 82% at 24 and 56% at 60 months mark. Of all analyzed risk factors only age exhibits a statistically significant relationship to survival (HR = 1.05, 95% CI = 10.3 - 1.07, p < 0.001). Treatment with chemotherapy showed definite trend toward superior survival with risk of dying from colon cancer been reduced by 42% (HR = 0.58, CI = 0.33–1.03). However, it was not statistically significant ( p=0.06). Number of removed lymph nodes was also showing possible relationship to the survival, although again not statistically significant (HR = 0.98, CI = 0.33–1.03, p=0.07). Other investigated factors were not significant correlates. Conclusions: In conclusion, our analysis showed that chemotherapy could potentially be beneficial for the survival of patients with Stage II colon cancer. In addition it seems that number of resected lymph nodes could be survival factor not only in Stage III, but also in Stage II disease. However, the most important factor for survival is still age of the patients No significant financial relationships to disclose.
TCT-543 Neointimal Coverage, Vessel Wall Healing and Major Evaginations after Everolimus-Eluting Absorb™ Bioresorbable Vascular Scaffold implantation Assessed with Serial Optical Coherence Tomography
Authors: Lisbeth Antonsen, Per Thayssen, Lisette Okkels Jensen
Journal: Journal of the American College of Cardiology (2015)
Predicting Risk of Infection and Graft vs. Host Disease (GvHD), and Response to Immunosuppression (ISP) in Allogeneic Hematopoietic Stem Cell Transplant (HSCT) Patients (pts) Using the Cylex®ImmuKnow® Assay: A Pilot Study.
Authors: Elias J. Anaissie, Jose A. Diaz, Monica L. Grazziutti, Marisa H. Miceli, Michele Fox-Cottler, Bart Barlogie
Journal: Blood (2006)
TCT-167 Drug Eluting Balloons Versus Balloon Angioplasty in Femoropopliteal and Infrapopliteal Vascular Disease Interventions: A Meta-analysis of Randomized Controlled Studies
Authors: Arun K. Kanmanthareddy, Avanija R. Buddam, Venkata M. Alla, Madhu Reddy, Claire Hunter, Dhanunjaya Lakkireddy, Scott M. Lilly
Journal: Journal of the American College of Cardiology (2015)
Grouping of Genetic Risk By the European Leukemia Net Classification Predicts Overall Survival and Relapse Incidence in Patients with Acute Myeloid Leukemia Undergoing Allogeneic Stem Cell Transplantation
Authors: Philipp G. Hemmati, Theis Terwey, Il-Kang Na, Christian Jehn, Lam G. Vuong, Philipp le Coutre, Bernd Dörken, Renate Arnold
Journal: Blood (2015)